Literature DB >> 24323988

Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients.

Marie-Anne Hospital1, Karine Viala, Sonia Dragomir, Vincent Levy, Fleur Cohen-Aubart, Jean Neil, Lucile Musset, Sylvain Choquet, Jean-Marc Leger, Véronique Leblond.   

Abstract

Entities:  

Keywords:  IgM-monoclonal gammopathy; Waldenstrom’s macroglobulinemia; neuropathy; unknown significance

Mesh：

Substances：

Year:  2013        PMID： 24323988      PMCID： PMC3856978          DOI： 10.3324/haematol.2013.087213

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

Review 1.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  M P T Lunn; E Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 2.  Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Meletios Athanasios Dimopoulos; Morie A Gertz; Efstathios Kastritis; Ramon Garcia-Sanz; Eva K Kimby; Veronique Leblond; Jean-Paul Fermand; Giampaolo Merlini; Pierre Morel; Enrica Morra; Enrique M Ocio; Roger Owen; Irene M Ghobrial; John Seymour; Robert A Kyle; Steven P Treon
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

3.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision.

Authors: 
Journal:  J Peripher Nerv Syst       Date:  2010-09       Impact factor: 3.494

4.  Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.

Authors:  Jean-Marc Léger; Karine Viala; Guillaume Nicolas; Alain Créange; Jean-Michel Vallat; Jean Pouget; Pierre Clavelou; Christophe Vial; Andreas Steck; Lucile Musset; Benoit Marin
Journal:  Neurology       Date:  2013-05-10       Impact factor: 9.910

Review 5.  Anti-myelin-associated glycoprotein neuropathy.

Authors:  Andreas J Steck; Anna K Stalder; Susanne Renaud
Journal:  Curr Opin Neurol       Date:  2006-10       Impact factor: 5.710

6.  The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS.

Authors:  Christopher J Klein; Joon-Shik Moon; Michelle L Mauermann; Steven R Zeldenrust; Yanhong Wu; Angela Dispenzieri; Peter J Dyck
Journal:  Can J Neurol Sci       Date:  2011-03       Impact factor: 2.104

7.  Treatment-related myelodysplasia following fludarabine combination chemotherapy.

Authors:  Constantine S Tam; John F Seymour; H Miles Prince; Melita Kenealy; Max Wolf; E Henry Januszewicz; David Westerman
Journal:  Haematologica       Date:  2006-11       Impact factor: 9.941

8.  Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases.

Authors:  B Chassande; J M Léger; A B Younes-Chennoufi; D Bengoufa; T Maisonobe; P Bouche; N Baumann
Journal:  Muscle Nerve       Date:  1998-01       Impact factor: 3.217

9.  Rituximab for polyneuropathy with IgM monoclonal gammopathy.

Authors:  J M F Niermeijer; M Eurelings; H L Lokhorst; W-L van der Pol; H Franssen; J H J Wokke; N C Notermans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09       Impact factor: 10.154

10.  Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.

Authors:  Xavier Leleu; Jérome Tamburini; Aldo Roccaro; Pierre Morel; Jacob Soumerai; Vincent Lévy; Mathieu Wemeau; Sandy Balkaran; Stephanie Poulain; Zachary R Hunter; Irene M Ghobrial; Steven P Treon; Veronique Leblond
Journal:  Clin Lymphoma Myeloma       Date:  2009-03
View more
  5 in total

Review 1.  Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Authors:  Meletios A Dimopoulos; Efstathios Kastritis; Roger G Owen; Robert A Kyle; Ola Landgren; Enrica Morra; Xavier Leleu; Ramón García-Sanz; Nikhil Munshi; Kenneth C Anderson; Evangelos Terpos; Irene M Ghobrial; Pierre Morel; David Maloney; Mathias Rummel; Véronique Leblond; Ranjana H Advani; Morie A Gertz; Charalampia Kyriakou; Sheeba K Thomas; Bart Barlogie; Stephanie A Gregory; Eva Kimby; Giampaolo Merlini; Steven P Treon
Journal:  Blood       Date:  2014-07-15       Impact factor: 22.113

Review 2.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 3.  Immunotherapy in Peripheral Neuropathies.

Authors:  Jean-Marc Léger; Raquel Guimarães-Costa; Cristina Muntean
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study.

Authors:  Pascal Hänggi; Butrint Aliu; Kea Martin; Ruben Herrendorff; Andreas Johann Steck
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-10

Review 5.  From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.

Authors:  Andrea Visentin; Stefano Pravato; Francesca Castellani; Marta Campagnolo; Francesco Angotzi; Chiara Adele Cavarretta; Alessandro Cellini; Valeria Ruocco; Alessandro Salvalaggio; Alessandra Tedeschi; Livio Trentin; Chiara Briani
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.